Jacobs Levy Equity Management
DBTX

Jacobs Levy Equity Management’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

Jacobs Levy Equity Management’s Portfolio DBTX Stock Details DBTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13,594
Closed -$117K – 1149
2021
Q2 		$117K Buy
+13,594
New +$120K ﹤0.01% 1008

Other funds holding DBTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Jacobs Levy Equity Management's DBTX Position: Q3 2021 in Review

Jacobs Levy Equity Management sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q3 2021, closing a stake of 13,594 shares — an estimated $117K sold.

Jacobs Levy Equity Management first reported a position in DBTX in Q2 2021 and held it in 1 quarter. The position peaked at $117K in Q2 2021. 36 funds tracked by Wall St. Rank hold DBTX as of Q3 2021.

  • Jacobs Levy Equity Management reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 13,594 Decibel Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $117K.
  • Jacobs Levy Equity Management first reported a position in Decibel Therapeutics, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Jacobs Levy Equity Management's Decibel Therapeutics, Inc. Common Stock position peaked at $117K in Q2 2021.
  • 36 funds tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2021, filed 15 Nov 2021.